Latest News

Latest News

The Future of Diagnostics Is Molecularly Precise

The Future of Diagnostics Is Molecularly Precise

The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...

read more
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Finding AF Before It Strikes: The Case for National Screening

Finding AF Before It Strikes: The Case for National Screening

There’s a concerning number of Australians living with a dangerous heart rhythm disorder - and many of them have no idea. Atrial fibrillation (AF) is a condition most people have never heard of and that’s a big problem, because it is already a silent cause of stroke. ...

read more
CAR-T Therapy Reaches Solid Tumours for the First Time

CAR-T Therapy Reaches Solid Tumours for the First Time

China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...

read more
Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic

Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic

The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...

read more
Weekly News Roundup | 22 June 2026

Weekly News Roundup | 22 June 2026

Life science news 22 June 2026: the FDA clears the first disease-modifying therapy for newly diagnosed childhood type 1 diabetes, the MHRA approves the UK's first cancer treatment delivered by on-body injector, and GSK wins approval for the first oral carbapenem...

read more
Clinical Trials Roundup | 19 June 2026

Clinical Trials Roundup | 19 June 2026

The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...

read more
Finding AF Before It Strikes: The Case for National Screening

Finding AF Before It Strikes: The Case for National Screening

There’s a concerning number of Australians living with a dangerous heart rhythm disorder - and many of them have no idea. Atrial fibrillation (AF) is a condition most people have never heard of and that’s a big problem, because it is already a silent cause of stroke. ...

read more
CAR-T Therapy Reaches Solid Tumours for the First Time

CAR-T Therapy Reaches Solid Tumours for the First Time

China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...

read more
Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic

Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic

The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...

read more
Weekly News Roundup | 22 June 2026

Weekly News Roundup | 22 June 2026

Life science news 22 June 2026: the FDA clears the first disease-modifying therapy for newly diagnosed childhood type 1 diabetes, the MHRA approves the UK's first cancer treatment delivered by on-body injector, and GSK wins approval for the first oral carbapenem...

read more
Clinical Trials Roundup | 19 June 2026

Clinical Trials Roundup | 19 June 2026

The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Beyond the Injection: The Future of Holistic GLP-1 Care

Beyond the Injection: The Future of Holistic GLP-1 Care

The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....

read more
Biotech IPO Surge: 2026’s First Half Beats 2025

Biotech IPO Surge: 2026’s First Half Beats 2025

Update 29th July 2026: For the completed first-half picture, including the June listings and Nasdaq's H1 figures, see Biotech IPO 2026: From Drought to Record-Breaking Deals. The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in...

read more
Why AI May Increase Cognitive Burden Before Reducing It

Why AI May Increase Cognitive Burden Before Reducing It

It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...

read more
Weekly News Roundup | 15 June 2026

Weekly News Roundup | 15 June 2026

Life science news 15 June 2026: GSK's $10.6 billion Nuvalent acquisition headlines a blockbuster M&A week, the MHRA approves the UK's first oral weight-loss semaglutide tablet, and the FDA clears a new adjuvant combination for kidney cancer in a landmark week for...

read more

Further News

Camizestrant Approval Makes ctDNA Progression a Regulatory Endpoint

The camizestrant approval granted by the US Food and Drug Administration on 4 September 2026 sets an oncology precedent. It is the first US clearance of a cancer therapy triggered by a resistance mutation found in blood. The agency made that claim itself. The trigger...

CBD Vaping: When Product Innovation Outpaces the Science

Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...

Neurodegeneration Pipeline 2026: Genetic Medicine Leads

Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...

The Future of Collagen Hydrogels in Regenerative Medicine

Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...

Novo Nordisk Halts Two IL-6 Heart Failure Trials for Futility

Novo Nordisk has stopped two Phase 3 IL-6 heart failure trials on the advice of an independent monitoring committee. The company notified trial investigators on Friday 4 September 2026. Trade press reported the decision on Monday 7 September. Both studies, HERMES and...

After EMBRAZE: The Wider Race to Preserve Muscle During GLP-1 Treatment

When results from the phase 2 EMBRAZE trial were published in Nature Medicine in June, apitegromab’s combination with tirzepatide became the most visible evidence yet that pharmacological muscle preservation during GLP-1 treatment might be achievable.¹ But...

Is RNA Potency the Problem? Creative Biolabs Webinar on saRNA Delivery

The next breakthrough in RNA therapeutics may depend less on making RNA more powerful and more on solving how efficiently it reaches and functions inside target cells. Creative Biolabs will host the upcoming webinar "Engineering saRNA Delivery Systems for...

Weekly News Roundup | 07 September 2026

Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...

Alexander Disease Treatment Approved: What It Means for UK Access

The first Alexander disease treatment is approved in the US. LSDN on the trial data, the Recordati licence and the outlook for UK access.

    Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven

    Novartis has reported that the pelacarsen trial missed its primary endpoint in 8,323 patients. Lp(a) fell; cardiovascular events did not.

      Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed

      Akeso reports an ivonescimab overall survival benefit over pembrolizumab in HARMONi-2, but no hazard ratio, median or data cutoff was disclosed.

        New Biology, New Opportunities in Women’s Health

        Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...

        Want to Be Part of the Next Chapter in Life Sciences Media?

         

        LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

         

         

        Don’t wait for the media to pick up your story. Be the media.

        See More Articles

        Want to Be Part of the Next Chapter in Life Sciences Media?

         

        LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

         

         

        Don’t wait for the media to pick up your story. Be the media.